[DIV28SUPER] Notes from the Field: Electronic Cigarette Use Among Middle and High School Students — United States, 2011–2 012

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6235a6.htm?s_cid=mm6235a6_w

"....E-cigarette experimentation and recent use doubled among U.S. middle and high school students during 2011–2012, resulting in an estimated 1.78 million students having ever used e-cigarettes as of 2012. Moreover, in 2012, an estimated 160,000 students who reported ever using e-cigarettes had never used conventional cigarettes. This is a serious concern because the overall impact of e-cigarette use on public health remains uncertain. In youths, concerns include the potential negative impact of nicotine on adolescent brain development (4), as well as the risk for nicotine addiction and initiation of the use of conventional cigarettes or other tobacco products....."

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 join our network

[DIV28SUPER] Reminder: Janet Hyde Graduate Student Research Grant

Posted on behalf of Olivia Moorehead-Slaughter [MooreheadO@parkschool.org]:

 

Janet Hyde Graduate Student Research Grant

 

Proposals are being sought for Hyde Graduate Student Research Grants. These grants, each up to $500, are awarded to doctoral psychology students to support feminist research. The grants are made possible through the generosity of Janet Shibley Hyde, Ph.D., who donates the royalties from her book, Half the Human Experience, to this fund. Past recipients of Hyde Graduate Student Research Grants are not eligible to apply. Because the purpose of this award is to facilitate research that otherwise might not be possible, projects that are beyond the data analysis stage are not eligible.

 

Please send all application materials attached to a single e-mail message to the Hyde Award Co-chair at the following address by September 15^th (for the fall deadline) or March 15^th (for the spring deadline):

Dr. Olivia Moorehead-Slaughter, MooreheadO@parkschool.org.

 

Requirements:

1. Cover page with project title, investigator's name, address, phone, fax, and e-mail address

2. A 100-word abstract

3. A proposal (5-pages maximum, double-spaced) addressing the project's purpose, theoretical rationale, and procedures, including how the method and data analysis stem from the proposed theory and purpose. [References are not included in this 5-page limit.]

4. A one-page statement articulating the study's relevance to feminist goals and importance to feminist research.

5. The expected timeline for progress and completion of the project (including the date of the research proposal committee meeting). The project timeline should not exceed two years.

6.  A faculty sponsor's recommendation, which includes why the research cannot be funded by other sources. This letter should be attached to the e-mail with the application materials. Please do not send it separately.

7. Status of IRB review process, including expected date of IRB submission and approval. Preference will be given to proposals that have received approval.

8. An itemized budget (if additional funds are needed to ensure completion of the project, please specify sources).  Funds cannot be used for tuition, living expenses, or travel to present research at a conference.

9. The applicant's curriculum vitae

 

All sections of the proposal should be typed and prepared according to APA style (e.g., please use 12-point font).

Applicants should submit no more than 2 files (i.e., one with the letter of recommendation and one with all the other required materials).

 

Proposals that fail to meet the guidelines described above will not be reviewed.

 

Review Process

A panel of psychologists will evaluate the proposals for theoretical and methodological soundness, relevance to feminist goals, applicant's training and qualifications to conduct the research, and feasibility of completing the project.

 

Other Requirements

Only one application will be accepted per student, for each application deadline.  Applicants who are involved in multiple projects that meet the submission requirements should choose the project that best fits the evaluation criteria (see “Review Process”).

 

Within 24 months of receipt of the grant, recipients are expected to submit to the Hyde committee co-chairs a complete and final copy of the research document (e.g., a copy of the thesis, dissertation or journal manuscript based on the sponsored research), along with a 500-word abstract for publication in Division 35 newsletter.  In addition, grant recipients shall acknowledge the funding source in the author's notes in all publications. Hyde award winners will be announced at the APA convention during Division 35 Social Hour. The names of the Hyde award winners may also be posted in Division 35 newsletter as well as on Division 35 web page and listserv.

 

Request for Abstracts from previous Hyde Award Winners
Brief abstracts of the work conducted by previous award recipients are printed in the newsletters. Previous award winners are highly encouraged to contact Dr. Olivia Moorehead-Slaughter, Hyde Award Co-chair, at MooreheadO@parkschool.org to submit a 500 word summary of their Hyde grant-funded research for consideration of publication in the Feminist Psychologist.

 

Questions and other communications may be sent to the committee co-chair:

Olivia Moorehead-Slaughter, Ph.D. Co-Chair, Phone: 617-414-4646, E-mail: MooreheadO@parkschool.org

 

 

[DIV28SUPER] NYTimes: E-Cigarette Makers=?utf-8?Q?=E2=80=99_Ads_Echo_Tobacco_=E2=80=99s?= Heyday

From The New York Times:

ADVERTISING: E-Cigarette Makers' Ads Echo Tobacco's Heyday

Antismoking advocates criticize e-cigarette manufacturers for using the same marketing methods as big tobacco did in the 1950s and '60s.

http://nyti.ms/188DrLF


Sent from my iPad
___________________ div28SUPER@lists.apa.org _____________________
Div28m members may post here subscribers corner: http://lists.apa.org

[DIV28SUPER] Reminder of deadline for Div 28/50 mid-year meeting symposia/breakout submissions

The Collaborative Perspectives on Addictions (Div 28/50) midyear meeting will be happening on February 28^th-March 1^st in lovely Atlanta Georgia. The theme is “Changing Addictive Behavior: Bench to Bedside and Back Again.”

 

The priority deadlines for breakout/symposia submissions is September 1^st (submit here: www.tinyurl.com/2014CPABreakout) and for poster sessions is October 1^st submit here: www.tinyurl.com/2014CPAPosters).   

 

Please join us for a wonderful meeting! 

 

Katie Witkiewitz, PhD

Division 28 CPA Program Co-Chair

Associate Professor

Department of Psychology

University of New Mexico

 

CALL FOR PROPOSALS

View the call for proposals at: www.tinyurl.com/2014CPACFP

 

·        Breakout/Symposia Proposals

o   Due September 1, 2013

o   www.tinyurl.com/2014CPABreakout 

·        Poster Proposals

o   Priority Deadline: October 1, 2013

o   www.tinyurl.com/2014CPAPosters

 

[DIV28SUPER] SAMHSA overdose prevention toolkit

----

Harm Reduction Coalition Applauds Release of SAMHSA Overdose Prevention Toolkit

Toolkit Lunch Marks International Overdose Awareness Day

In preparations to mark International Overdose Awareness Day on August 31^st the Office of National Drug Control Policy (ONDCP) and the Substance Abuse and Mental Health Services Administration (SAMHSA) have released a new Opioid Overdose Prevention Toolkit. The toolkit aims to reduce the number of fatal opioid overdoses by providing education for clinicians, patients, communities, first responders, overdose survivors and family members.

The overdose prevention toolkit highlights the importance of access to naloxone, a medication that reverses the effects of overdose from opioids (heroin or prescription painkillers). "This toolkit marks growing federal support and leadership for expanding use and availability of naloxone as a central component of a comprehensive overdose prevention strategy," noted Daniel Raymond, Harm Reduction Coalition's Policy Director. "We're seeing a tremendous groundswell of support across the country for addressing overdose through overdose education and naloxone distribution programs, from parents groups and community coalitions, medical societies, substance abuse treatment and recovery groups, and state legislatures."

"Naloxone is safe, cheap and effective, and overdose prevention programs which provide naloxone – whether through health departments, first responders, harm reduction organizations, or drug treatment facilities -- are saving lives," said Dr. Sharon Stancliff, Medical Director of the Harm Reduction Coalition. Naloxone is an opioid antagonist with no potential for extra-medical use and is the gold standard medication for counteracting and reversing the effects of opioid overdose. The Harm Reduction Coalition (HRC) has been in the forefront of this push for naloxone, through advocating and providing technical assistance for overdose prevention for nearly a decade. As part of this on going work, HRC trains people who use opioids, along with their peers, allies, friends and family members on overdose prevention, recognition and response, as well as on how to use naloxone to reverse opioid overdose. As support for naloxone grows so has the evidence base. A 2012 report authored by Harm Reduction Coalition's DOPE Project Manager and colleagues published by the Centers for Disease Control and Prevention (CDC) stated that in a single year, 10,171 overdoses had been reversed by using naloxone—or around 20% of people (53,032) trained and provided with naloxone by community-based organizations. 

Overdose claimed the lives of 38,329 people the US in 2010, over 100 persons every day, exceeding the number of lives lost in road and traffic accidents or gun violence. According to the CDC, opioid analgesics (painkillers) alone, have claimed the lives of 125,000 people in the last decade. Currently, the overdose epidemic currently shows no little sign of abating and is best characterized by a steady upward trend, with a roughly five-fold increase in fatal overdoses since 1990.  

On the eve of International Overdose Awareness Day the Harm Reduction Coalition welcomes the release of the toolkit and congratulates both ONDCP and SAMHSA for a coordinated, evidence-based response to overdose prevention and for endorsing a harm reduction intervention that can save lives. Harm Reduction Coalition urges policy makers and communities to integrate broader access to naloxone into their overdose prevention strategies. In the words of ONDCP Deputy Director Michael Botticelli, "We must do more…. We have lost too many loved ones to overdose, and the deadly disease of addiction has remained for too long in the shadows. It is time to speak out."

For more information the Harm Reduction Coalition's ongoing work on overdose prevention, follow the Drug Overdose Prevention & Education Project (DOPE) Project on facebook and twitter.

 
http://store.samhsa.gov/product/SMA13-4742

 

Daniel Raymond
Policy Director
Harm Reduction Coalition
22 W. 27th Street, 5th Floor
New York, NY 10001
(212) 213-6376 x29
Fax: (212) 213-6582
raymond@harmreduction.org
www.harmreduction.org

--

--

Kelly Dunn, Ph.D.
Instructor
Johns Hopkins University School of Medicine
5510 Nathan Shock Drive
Baltimore, MD 21224
BPRU Phone: (410) 550-2254
Fax: (410) 550-0030
 
WARNING:  E-mail sent over the Internet is not secure.  Information sent by e-mail may not remain confidential.
DISCLAIMER:  This e-mail is intended only for the individual to whom it is addressed.  It may be used only in accordance with applicable laws.  If you received this e-mail by mistake, notify the sender and destroy the e-mail

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 join our network

[DIV28SUPER] NIH Funding Opportunity Network K18 RFA

 

 

[DIV28SUPER] CPDD Executive Officer

CPDD EXECUTIVE OFFICER
 
The Executive Committee and Board of Directors of the College on Problems of Drug Dependence (CPDD: www.cpdd.org) are pleased to announce the search for a new Executive Officer (E.O.) who will succeed Dr. Martin Adler. CPDD has been in existence since 1929 and is the longest standing group in the USA addressing problems of drug dependence and abuse. Currently, CPDD has over 1,000 members and the organization serves as an interface among governmental, industrial and academic communities maintaining liaisons with regulatory and research agencies as well as educational, treatment, and prevention facilities in the drug abuse field.

The responsibilities of the E.O. are to represent CPDD in dealings with government, industry, academia, and other organizations as related to policy positions, joint initiatives, funding and other issues that may arise. The E.O. is ad hoc to all committees of CPDD. He/she is responsible for overseeing the work of the various committees of CPDD, giving advice and direction when needed, and preparing, in collaboration with the Director of the Executive Office (Ellen Geller) the annual meeting grant from NIDA, on which he/she is both the P.I. and the Signing Officer for the organization. The E.O. is the official signator for CPDD in all legal matters, including federal, state, and local forms, as well as items related to insurance. The E.O. serves as a non-voting member of the Executive Committee and is a member of the Finance Committee. The E.O. works with Friends of NIDA and Von Scoyoc in educating members of Congress on issues related to drug abuse funding and policy. The E.O. also assists in setting up meetings with which CPDD is associated, including the annual scientific meeting of CPDD held at various locations in June of each year.

In order to accomplish the larger goals of the organization, the E.O. has to be able to work with all of the constituencies of the organization, including the Director of the Executive Office, the membership, the Officers, the Board of Directors (BOD), and the Committee Chairs. Many issues arise that require negotiating skills, people skills, and good judgment. It is the responsibility of the E.O. to integrate all of CPDD activities that have been authorized by the BOD and the officers of CPDD. In summary, the E.O. has a leadership role in CPDD and is responsible to the Executive Committee and BOD of CPDD. 
                                                                                                                         
Characteristics strongly recommended for candidates:
Doctoral degree (Ph.D., M.D., Psy.D., etc) and a faculty appointment at a university, medical school or other institution at the level of Professor or equivalent;
History of NIH funding as a PI in the fields covered by CPDD's membership, especially addiction and drug abuse;
Documented history of administrative and/or leadership experience;
Substantial history of service to CPDD through membership on committees, elected member of BOD, or previous elected officer of CPDD;
History of robust attendance (i.e., at least 7 of last 10 years) and presenting at CPDD; and
Ability to commit up to 50% of effort for the position.
                                                     
Interested candidates should submit a one-page letter of interest, recent CV, and answers to the questions below to Richard De La Garza, II, Ph.D. (Chair of the E.O. Search Committee) by October 15, 2013. All documents should be submitted electronically as one file to rg12@bcm.edu. Questions about the position should be E-mailed directly to Dr. De La Garza.
 
Please address the following (maximum 3-pages):
Describe your scientific background and experience.
Describe current responsibilities and how you will reallocate effort to accommodate this position.
Describe your administrative/leadership experience.  
How available would you be to travel to Washington DC or other locations for CPDD business?
Discuss your vision for CPDD and how CPDD can best serve the substance abuse research community in the future.  
How do you envision interacting with the CPDD office* at Temple University?
                                 *Information provided upon request